Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: November 13, 2024
Context: This filing incorporates by reference a press release (Exhibit 99.1) dated November 13, 2024. The document serves to update U.S. investors on material events disclosed in the press release and incorporates this information into the company's registration statements on Form F-3 and Form S-8.
Key Financial Metrics
The provided filing text does not contain specific financial data. It is a cover document referencing an external press release. Consequently, the following metrics are not available in this text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not explicitly detail material changes versus prior periods. It indicates that the substantive information regarding material events is contained within the incorporated press release (Exhibit 99.1), the text of which is not included in the provided input.
Guidance, Outlook, and Risks
Management Commentary: The filing references a quote from Jonathan Dickinson, Chairman of the Executive Board and CEO, but the content of the quote is excluded from the incorporation by reference and is not present in the provided text.
Guidance and Risks: No specific guidance, outlook, risk factors, or contingencies are detailed in the provided Form 6-K text.
Investor Verification Checklist
- Review the full text of the Press Release dated November 13, 2024 (Exhibit 99.1) to understand the specific material event triggering this filing.
- Verify the content of the CEO's quote referenced in the press release, as it was excluded from the incorporation by reference in this document.
- Check the company's Form 20-F for the most recent audited financial statements, as this 6-K does not contain financial tables.
- Confirm the status of the registration statements (Form F-3 File No. 333-276164 and Form S-8 File No. 333-282031) to which this report is incorporated.